M&A Deal Summary

Alexion Pharmaceuticals Acquires Achillion Pharmaceuticals

On October 16, 2019, Alexion Pharmaceuticals acquired life science company Achillion Pharmaceuticals for 930M USD

Acquisition Highlights
  • This is Alexion Pharmaceuticals’ 6th transaction in the Life Science sector.
  • This is Alexion Pharmaceuticals’ 4th largest (disclosed) transaction.
  • This is Alexion Pharmaceuticals’ 5th transaction in the United States.
  • This is Alexion Pharmaceuticals’ 1st transaction in Pennsylvania.

M&A Deal Summary
Date 2019-10-16
Target Achillion Pharmaceuticals
Sector Life Science
Buyer(s) Alexion Pharmaceuticals
Deal Type Add-on Acquisition
Deal Value 930M USD
Advisor(s) Centerview Partners (Financial)
Skadden, Arps, Slate, Meagher & Flom (Legal)

Target

Achillion Pharmaceuticals

Blue Bell, Pennsylvania, United States
Achillion Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on advancing its oral small molecule complement inhibitors into late-stage development and commercialization. Research has shown that an overactive complement system plays a critical role in multiple disease conditions including the therapeutic areas of nephrology, hematology, ophthalmology, and neurology.

Search 201,157 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Alexion Pharmaceuticals

Boston, Connecticut, United States
Category Company
Founded 1992
Sector Life Science
Employees3,082
Revenue 6.1B USD (2020)
DESCRIPTION

Alexion Pharmaceuticals is a biopharmaceutical company focused on developing and delivering life-transforming therapies for patients with severe and life-threatening diseases that are also ultra-rare. Patients with these devastating diseases often have no effective treatment options, and they and their families suffer with little hope. Alexion Pharmaceuticals was formed in 1992 and is based in New Haven, Connecticut.

DEAL STATS #
Overall 7 of 9
Sector (Life Science) 6 of 8
Type (Add-on Acquisition) 7 of 9
State (Pennsylvania) 1 of 1
Country (United States) 5 of 7
Year (2019) 1 of 1
Size (of disclosed) 4 of 7
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2018-09-26 Syntimmune

Boston, Massachusetts, United States

Syntimmune is a clinical-stage biotechnology company developing differentiated drug candidates in a wide range of autoimmune diseases. Drawing on the pioneering research of its scientific founders, the company is advancing novel therapies based on its deep expertise in the biology of the neonatal Fc receptor (FcRn) and its complex role in the pathogenesis of IgG-mediated autoimmune diseases. Syntimmune’s lead candidate, SYNT001, is a monoclonal antibody that specifically blocks FcRn-IgG interactions and is being studied in multiple Phase 1b/2a trials for the treatment of IgG-mediated autoimmune diseases. Syntimmune is headquartered in Boston, Mass. and was founded in 2013.

Buy $1.2B
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2020-05-05 Portola Pharmaceuticals

South San Francisco, California, United States

Portola Pharmaceuticals, Inc. is a biopharmaceutical company, discovers and develops therapeutics for cardiovascular and autoimmune diseases. Portola Pharmaceuticals was founded in 2003 and is based in South San Francisco, California.

Buy -
Mergr

Product

Company

Legal